Nima Rezaei

Artificial intelligence-driven biomarker discovery and response prediction in cancer immunotherapy: a pan-cancer perspective

Cancer immunotherapy has transformed medical oncology, while individual’s therapeutic response to treatment is difficult because of the diverse nature and features of tumors and low precision and accuracy of markers, such as PD-L1, Tumor Mutational Burden (TMB), and Microsatellit...

Genotype–phenotype analysis in 333 individuals with heterozygous variants in NFKB1

Heterozygous germline variants in NFKB1 can be classified into variants with “known protein defect” and “unknown protein effect.” However, beyond this, NFKB1 variants may be additionally categorized into at least eight distinct variant classes. We conducted a literature review of...